Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IMMUCELL CORP /DE/ (ICCC)

ImmuCell Q3 2026 Preliminary Sales Rise 46% to $8.0 Million

Positive Impact 3 of 5 earnings Written later

ImmuCell Corporation reported preliminary, unaudited third-quarter 2026 total sales of $8.0 million, a 46.0% increase from the third quarter of 2025, and nine-month sales of $25.6 million, up 27.8%. The company said the comparison was aided in part by depressed third-quarter 2025 sales caused by high distributor purchases in the second quarter of 2025. Full financial results are due on a conference call on November 13, 2026, and the company will stop issuing early sales reports.

Key points

  • Q3 2026 total sales were $8.0 million, up 46.0%; domestic sales were $6.9 million, up 29.2%
  • Nine-month 2026 total sales were $25.6 million, up 27.8% from the nine months ended September 30, 2025
  • Q3 2025 comparison was depressed by high distributor purchases in Q2 2025
  • Full results will be discussed on a conference call on Friday, November 13, 2026, at 9:00 AM ET

The filing

CompanyIMMUCELL CORP /DE/ (ICCC)
Form8-K, current report
Filed with the SECOct 13, 2026, 6:01 AM ET
Accession number0001437749-26-032465

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.